Analyst consensus rating
Spyre Therapeutics Analyst Rating: Strong Buy
Direct answer
Spyre Therapeutics's consensus rating is Strong Buy.
13 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $120.08.
Forecast evidence checked September 21, 2026.
Get free Spyre Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $90.25
- Average price target
- $120.08
- High price target
- $130.00
- Low price target
- $97.00
- Low target gap
- +7.5%
- Target upside
- +33%
- High target gap
- +44%
- Target range width
- 36.6%
- Consensus rating
- Strong Buy
- Analysts
- 13
- Evidence date
- September 21, 2026
- Valid through
- September 28, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Spyre Therapeutics?
Spyre Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $120.08.
How far are Spyre Therapeutics's low and high targets from the recorded price?
The low target implies +7.5%, while the high target implies +44%.
How many analysts are included in Spyre Therapeutics's consensus?
The verified consensus includes 13 analysts.
How is Spyre Therapeutics's target upside or downside calculated?
The average target of $120.08 is divided by the recorded price of $90.25, then one is subtracted to produce +33%. This does not guarantee a future return.
When was Spyre Therapeutics's analyst forecast verified?
The data was verified on 2026-09-21. The dataset is valid through 2026-09-28.